AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02874287
Drug: Hydroxychloroquine Sulfate Tablets
RxNorm normalized name: Hydroxychloroquine Sulfate Tablets
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Trial: NCT00978471
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
Trial: NCT00276874
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole; 0-30 mg; oral; daily
Trial: NCT04148820
Drug: Aspirin, Atorvastatin, Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardiovascular drugs will be administered all together every day at the same time
Trial: NCT01365065
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat 400mg (4 x 100mg) orally daily for 14 days
Trial: NCT00036296
Drug: talampanel
RxNorm normalized name: Talampanel
DrugBank: Talampanel (DB04982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg per day divided into 3 doses for 22 days
Trial: NCT03807882
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
Trial: NCT00003976
Drug: indisulam
RxNorm normalized name: Indisulam
DrugBank: Indisulam (DB06370)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00515073
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg/m\^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m\^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
Trial: NCT03203070
Drug: Metamizol iv
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesia iv with Metamizol 2g/8h will be administered.
Trial: NCT01356927
Drug: DMPA
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
Trial: NCT01356927
Drug: Etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
Trial: NCT00515073
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg IV given 30 minutes prior to chemotherapy
Trial: NCT00515073
Drug: Cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg IV given 30 minutes prior to chemotherapy
Trial: NCT00515073
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg IV given 30 minutes prior to chemotherapy
Trial: NCT00003865
Drug: toremifene
RxNorm normalized name: Toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01498328
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
Trial: NCT01498328
Drug: Rindopepimut (CDX-110) with GM-CSF
RxNorm normalized name: sipuleucel-T
DrugBank: Rindopepimut (DB05374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
Trial: NCT01498328
Drug: KLH
RxNorm normalized name: KLH
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
Trial: NCT00785018
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
Trial: NCT00785018
Drug: Endotoxin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Trial: NCT04353479
Drug: Camrelizumab(SHR-1210)
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A humanized monoclonal immunoglobulin
Trial: NCT00052780
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00052780
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00600535
Drug: Stage 1 Group 1: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
Trial: NCT00600535
Drug: Stage 1 Group 2: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
Trial: NCT00600535
Drug: Stage 2: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
Trial: NCT00600535
Drug: Stage 3: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablets/day orally for 12 cycles (28 days/cycle).
Trial: NCT00600535
Drug: Stage 4: abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
Trial: NCT02919696
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT03773367
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Trial: NCT03773367
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Trial: NCT02035501
Drug: L-Tyrosine
RxNorm normalized name: L-tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04353479
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A DNA methyltransferase inhibitor
Trial: NCT01245387
Drug: Pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
Trial: NCT00662220
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25-29 mg/kg/day
Trial: NCT00662220
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12-15 mg/kg/day
Trial: NCT03107663
Drug: ⁸⁹Zr-Df-IAB22M2C Infusion
RxNorm normalized name: Zirconium zr 89-df-iab22m2c
DrugBank: Zirconium (89Zr) crefmirlimab berdoxam (DB19157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
Trial: NCT04489459
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
Trial: NCT04489459
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
Trial: NCT00929903
Drug: pazopanib hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT03197961
Drug: DMPA
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
Trial: NCT00623025
Drug: Creon 25000
RxNorm normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 9 capsules Creon 25000 per day
Trial: NCT02497391
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT01737502
Drug: Auranofin
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01737502
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04457960
Drug: JNJ-66525433
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-66525433 oral capsules.
Trial: NCT02883166
Drug: abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: integested with a continental breakfast
Trial: NCT02815410
Drug: levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
Trial: NCT02856698
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose use according to the product technical sheet
Trial: NCT02856698
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose use according to the product technical sheet
Trial: NCT01978535
Drug: Normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
Trial: NCT01658852
Drug: metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02857582
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator to treatment with ACHIM
Trial: NCT02857582
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary treatment for C diff in all treatment arms
Trial: NCT01469234
Drug: loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loratadine, one 10 mg tablet, orally
Trial: NCT01469234
Drug: fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fexofenadine, one 180 mg tablet, orally
Trial: NCT01469234
Drug: placebo to loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet, orally
Trial: NCT01469234
Drug: placebo to fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet, orally
Trial: NCT03947814
Drug: Pimodivir
RxNorm normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
Trial: NCT02748330
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor
Trial: NCT02748330
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel
Trial: NCT02748330
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid
Trial: NCT01736462
Drug: Mapracorat
RxNorm normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
Trial: NCT02958501
Drug: Colecalciferol
RxNorm normalized name: colecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00423514
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00423514
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00423514
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00423514
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00423514
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00255762
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00255762
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01035099
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;
Trial: NCT04049760
Drug: migalastat HCl 150 mg
RxNorm normalized name: Galafold 123 MG (as migalastat HCl 150 MG) Oral Capsule
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: migalastat HCl 150 mg capsule
Trial: NCT01035099
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
Trial: NCT00053092
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03179891
Drug: Diazepam Buccal Film 12.5 mg
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
Trial: NCT01175356
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01175356
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01175356
Drug: Etoposide Phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01175356
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01175356
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01175356
Drug: Topotecan Hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01175356
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04722575
Drug: Cobimetinib 20 MG Oral Tablet
RxNorm normalized name: cobimetinib 20 MG Oral Tablet
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
Trial: NCT04722575
Drug: Vemurafenib 240 Mg Oral Capsule
RxNorm normalized name: Vemurafenib 240 mg oral capsule
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
Trial: NCT04722575
Drug: Atezolizumab 1200 MG in 20 ML Injection
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
Trial: NCT03516812
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03516812
Drug: Testosterone Enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT03516812
Drug: Testosterone Cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT01687140
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Trial: NCT04541979
Drug: aerosolized DNase
RxNorm normalized name: Recombinant deoxyribonuclease (DNAse)
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNase
Trial: NCT00180830
Drug: Glivec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00180830
Drug: Gleevec
RxNorm normalized name: Gleevec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03952637
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: We are proposing the use of immune modulation to transiently deplete B-cells using rituximab. It will be infused at -21 days and -14 days before gene transfer.
Trial: NCT03952637
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus is a macrocytic lactone that inhibits T lymphocyte activation and proliferation by inhibiting activation of mammalian Target of Rapamycin (mTOR) kinase that suppresses cytokinedriven T-cell proliferation. We plan to give sirolimus from day -21 to Day 90 with option to extend to day 365 if clinically indicated.
Trial: NCT03952637
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive IV methylprednisolone 1 mg/kg or a maximum dose of 50 mg, 60-120 minutes prior to vector administration on day 0 to mitigate potential acute innate immune response against the vector.
Trial: NCT03952637
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (oral solution, dose 0.5 mg/kg) will be taken daily on Days 1-3.
Trial: NCT04541979
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NaCl 0.9%, isotonic saline